18979-61-8 | 4-Butylresorcinol

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$6.00	$4.00
10mg	98%	in stock	$16.00	$11.00
250mg	98%	in stock	$24.00	$17.00
1g	98%(GC)	in stock	$96.00	$67.00
5g	98%	in stock	$179.00	$125.00
10g	98%	in stock	$261.00	$183.00
25g	98%	in stock	$651.00	$456.00

Description

• Catalog Number: AB11224
• Chemical Name: 4-Butylresorcinol
• CAS Number: 18979-61-8
• Molecular Formula: C10H14O2
• Molecular Weight: 166.2170
• MDL Number: MFCD01684800
• SMILES: CCCCc1ccc(cc1O)O

Computed Properties

• Complexity: 125
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 12
• Hydrogen Bond Acceptor Count: 2
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 3
• XLogP3: 2.4

Literature

• Hypopigmentary effects of 4-n-butylresorcinol and resveratrol in combination.

  Die Pharmazie 20120601

• Adamantyl N-benzylbenzamide: new series of depigmentation agents with tyrosinase inhibitory activity.

  Bioorganic & medicinal chemistry letters 20120301

• Topical hypopigmenting agents for pigmentary disorders and their mechanisms of action.

  Annals of dermatology 20120201

• Efficacy and safety of liposome-encapsulated 4-n-butylresorcinol 0.1% cream for the treatment of melasma: a randomized controlled split-face trial.

  The Journal of dermatology 20100401

• The Efficacy and Safety of 4-n-butylresorcinol 0.1% Cream for the Treatment of Melasma: A Randomized Controlled Split-face Trial.

  Annals of dermatology 20100201

• Quasi-drugs developed in Japan for the prevention or treatment of hyperpigmentary disorders.

  International journal of molecular sciences 20100101

• Studies on depigmenting activities of dihydroxyl benzamide derivatives containing adamantane moiety.

  Bioorganic & medicinal chemistry letters 20090301

• Evaluation of efficacy and safety of rucinol serum in patients with melasma: a randomized controlled trial.

  The British journal of dermatology 20070501

• Inhibitory effects of 4-n-butylresorcinol on tyrosinase activity and melanin synthesis.

  Biological & pharmaceutical bulletin 20051201